The Life Sciences team advised AbSci on its $125 million crossover financing.
AbSci is a leading synthetic biology company enabling drug discovery and biomanufacturing of next-generation biotherapeutics.
Proceeds will support AbSci's continued growth, including research and development activities and other strategic investments. Key areas of focus are integration and training of the Denovium Engine™ deep learning artificial intelligence platform AbSci acquired in January 2021, and ongoing expansion of core discovery capabilities including non-standard amino acid technologies.
The Goodwin team was led by Maggie Wong and Kingsley Taft.
For more details, read the press release and articles in Portland Business Journal and GeekWire.